Pharmaceuticals, Biotechnology and Life Sciences
IMV is preparing to advance a DPX-based vaccine candidate for COVID-19, which is on track to enter into clinical trials later this summer.
Launched development program for a DPX-based vaccine candidate against COVID-19 Reported updated Phase 2 data from DeCidE1 study in advanced…
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates…
Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable clinical benefit with…
Company to host conference call following ASCO presentation on June 2 to discuss updated clinical data DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV…
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive…
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational…